|
🐜
|
Improved survival with MEK inhibition in BRAF-mutated melanoma.
25 auth.
K. Flaherty,
C. Robert,
P. Hersey,
P. Nathan,
C. Garbe,
M. Milhem,
L. Demidov,
J. Hassel,
P. Rutkowski,
P. Mohr,
R. Dummer,
U. Trefzer,
J. Larkin,
J. Utikal,
B. Dréno,
...
M. Nyakas,
M. Middleton,
J. Becker,
M. Casey,
L. Sherman,
Frank Wu,
D. Ouellet,
Anne-Marie Martin,
K. Patel,
D. Schadendorf
|
10 |
2012 |
10
🐜
|
|
🐜
|
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
35 auth.
G. Long,
D. Stroyakovskiy,
H. Gogas,
E. Levchenko,
F. de Braud,
J. Larkin,
C. Garbe,
T. Jouary,
A. Hauschild,
J. Grob,
V. Chiarion Sileni,
C. Lebbé,
M. Mandalà,
M. Millward,
A. Arance,
...
I. Bondarenko,
J. Haanen,
J. Hansson,
J. Utikal,
V. Ferraresi,
N. Kovalenko,
P. Mohr,
V. Probachai,
D. Schadendorf,
P. Nathan,
C. Robert,
A. Ribas,
D. Demarini,
J. Irani,
M. Casey,
D. Ouellet,
Anne-Marie Martin,
N. Le,
K. Patel,
K. Flaherty
|
10 |
2014 |
10
🐜
|
|
🐜
|
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
19 auth.
K. Flaherty,
C. Robert,
P. Hersey,
P. Nathan,
C. Garbe,
M. Milhem,
L. Demidov,
J. Hassel,
P. Rutkowski,
P. Mohr,
...
R. Dummer,
U. Trefzer,
J. Larkin,
J. Utikal,
B. Dréno,
M. Casey,
L. Sherman,
Frank Wu,
D. Schadendorf
|
10 |
2012 |
10
🐜
|
|
🐜
|
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
12 auth.
K. Blackwell,
H. Burstein,
A. Storniolo,
H. Rugo,
G. Sledge,
M. Koehler,
...
C. Ellis,
M. Casey,
S. Vukelja,
J. Bischoff,
J. Baselga,
J. O’Shaughnessy
|
9 |
2010 |
9
🐜
|
|
🐜
|
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
24 auth.
D. Cameron,
M. Casey,
M. Press,
D. Lindquist,
T. Pieńkowski,
C. Romieu,
S. Chan,
A. Jagiełło-Gruszfeld,
B. Kaufman,
J. Crown,
...
A. Chan,
M. Campone,
P. Viens,
N. Davidson,
V. Gorbounova,
J. Raats,
D. Skarlos,
B. Newstat,
D. Roychowdhury,
P. Paoletti,
C. Oliva,
S. Rubin,
S. Stein,
C. Geyer
|
9 |
2008 |
9
🐜
|
|
🐜
|
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
22 auth.
A. Ravaud,
R. Motzer,
H. Pandha,
D. George,
A. Pantuck,
Anup Patel,
Yen‐Hwa Chang,
B. Escudier,
F. Donskov,
A. Magheli,
...
G. Cartenì,
B. Laguerre,
P. Tomczak,
J. Breza,
P. Gerletti,
M. Lechuga,
Xun Lin,
J. Martini,
K. Ramaswamy,
M. Casey,
M. Staehler,
J. Patard
|
9 |
2016 |
9
🐜
|
|
🐜
|
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
14 auth.
H. Gómez,
D. Doval,
M. A. Chavez,
P. Ang,
Z. Aziz,
S. Nag,
C. Ng,
S. Franco,
L. Chow,
M. Arbushites,
...
M. Casey,
M. Berger,
S. Stein,
G. Sledge
|
8 |
2008 |
8
🐜
|
|
🐬
|
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
D. Cameron,
M. Casey,
C. Oliva,
B. Newstat,
Bradley Imwalle,
C. Geyer
|
8 |
2010 |
8
🐬
|
|
🐜
|
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
18 auth.
M. Gross-Goupil,
T. Kwon,
M. Eto,
Dingwei Ye,
H. Miyake,
S. Seo,
S. Byun,
J. Lee,
V. Master,
J. Jin,
...
R. Debenedetto,
R. Linke,
M. Casey,
B. Rosbrook,
M. Lechuga,
O. Valota,
E. Grande,
D. Quinn
|
7 |
2018 |
7
🐜
|
|
🐜
|
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
16 auth.
A. Santiago-Walker,
R. Gagnon,
J. Mazumdar,
M. Casey,
G. Long,
D. Schadendorf,
K. Flaherty,
R. Kefford,
A. Hauschild,
P. Hwu,
...
P. Haney,
Anne O’Hagan,
J. Carver,
V. Goodman,
J. Legos,
Anne-Marie Martin
|
7 |
2015 |
7
🐜
|
|
🐜
|
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
21 auth.
R. Motzer,
A. Ravaud,
J. Patard,
H. Pandha,
D. George,
Anup Patel,
Yen‐Hwa Chang,
B. Escudier,
F. Donskov,
A. Magheli,
...
G. Cartenì,
B. Laguerre,
P. Tomczak,
J. Breza,
P. Gerletti,
M. Lechuga,
Xun Lin,
M. Casey,
L. Serfass,
A. Pantuck,
M. Staehler
|
7 |
2018 |
7
🐜
|
|
🐜
|
Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
11 auth.
F. Ahmed,
Nancy C. Ahmed,
P. Vos,
C. Bonnerup,
J. Atkins,
M. Casey,
...
G. Nuovo,
W. Naziri,
J. Wiley,
H. Mota,
R. Allison
|
7 |
2013 |
7
🐜
|
|
🐜
|
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
16 auth.
Yoon-Koo Kang,
T. Yau,
J. Park,
H. Lim,
T-Y Lee,
S. Obi,
S. Chan,
S. Qin,
R. Kim,
M. Casey,
...
Connie Chen,
H. Bhattacharyya,
J. A. Williams,
O. Valota,
D. Chakrabarti,
M. Kudo
|
6 |
2015 |
6
🐜
|
